EDEN PRAIRIE, Minn., March 30, 2021 /PRNewswire/ — NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today that CEO Dave Rosa will make a live appearance on the Big Biz Show, April 5, 2021, 1:15 CST. Rosa will discuss how electrical stimulation is changing treatment modalities today, what the future may hold for this therapy and NeuroOne’s potential role.
The Big Biz Show, a syndicated television program that has been running for over 20 years, combines business, personal finance and investing topics with lighthearted comedy. Hosted by Emmy-award winning Bob Sullivan and his partner comedian Russ Stolnack, the show can be watched on the following media outlets:
Check local listings or follow NeuroOne on social media to stay up to date on this broadcast.
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit https://www.n1mtc.com.
On February 23, 2021, the Company announced it had successfully met the first performance milestone in the distribution and development agreement signed with Zimmer Biomet on July 20, 2020. In addition to acquiring exclusive global distribution rights to NeuroOne’s Evo™ (Evo) patented electrode technology, the partnership also offered the potential for NeuroOne to earn back-end milestone payments if certain events were met within a specified time frame.
NeuroOne received FDA clearance for its Evo cortical technology in November 2019.
In partnership with Mayo Clinic, Wisconsin Alumni Research Foundation (WARF) and other prominent academic medical centers, the Company began developing its cortical electrode technology in 2015. The Company initially focused its efforts on the epilepsy and intraoperative tumor monitoring markets. NeuroOne intends to continue to develop the technology for use in therapeutic applications for Parkinson’s disease, epilepsy and pain management due to failed back surgery procedures.